• 11 September 2006
  • News
  • By

Panacea gets pre-qualification certification

Panacea gets pre

Panacea gets pre-qualification certification

Panacea Biotec has received pre-qualification accreditation from the World Health Organization (WHO) for the supply of recombinant Hepatitis B vaccine to UN agencies.

"There has been constant growth in Panacea Biotec revenue due to strong vaccine sales and our inclusion in the list of pre-qualified suppliers of WHO will significantly enhance our presence in this segment, resulting in better sales volumes and profitability," said Rajesh Jain, joint managing director, Panacea Biotec.

The overall estimated market for Hepatitis-B vaccine and its combinations as per UNICEF and PAHO for year 2007 is around 158 million doses, which is estimated to go up to 185 million doses in 2008 and 888 million doses in 2009. In terms of revenues, it would amount to around $270 million in 2007, going up to $390 million in 2008 and $1 billion in 2009. In 2000, there were 5.7 million cases of acute Hepatitis-B infection and more than 521,000 deaths from Hepatitis-B related disease, worldwide. The World Health Organization, in the year 1999, called for all children to receive the Hepatitis-B vaccine, and 116 countries have added this vaccine to their routine immunization program.

In India, Hepatitis-B vaccine is in the process of being listed in the list of "essential vaccines", but there exists a huge market in the private sector, keeping in view the birth cohort of around 25 million new borne every year. Panacea Biotec was amongst the first few Indian companies to have introduced Hepatitis-B vaccine in the country.

At present, it is marketing its Hepatitis-B vaccine and combination vaccines through its joint venture company, Chiron Panacea Vaccines having brand names-Enivac HB, Easyfour (Hepatitis B + DPT) and Easyfive (Hepatitis B + DTP + Hib).

The main aim of Hepatitis B immunization strategies is to prevent chronic Hepatitis-B virus (HBV) infection and its serious consequences, including liver cirrhosis and hepatocellular cancer.


Avesthagen selected Red Herring 100 Asia Winner

Bangalore-based Avestha Gengraine Technologies (Avesthagen) has been declared as a Red Herring Magazine 100 Asia Winner for 2006 for disruptive innovation.

The award recognizes that Avesthagen is an emerging star in Asia and follows a stringent evaluation of its business model, profitability forecasts, management team and technology. The judging panel, comprising the Red Herring Editorial Team, received over 600 submissions from across the continent.

"It is very gratifying to receive this award weeks after we announced a significant, long-term strategic collaboration with Group Limagrain, the fourth largest seeds group in the world, to develop superior seeds for the Indian and global market," said Dr Villoo Morawala Patell, founder and CEO, Avesthagen.

"Such deals and this award underline the potential of our company, which aims to bring its first product to market in 2007. We are working with leading organizations including Nestle, AstraZeneca, Novartis, Cipla and bioMerieux. Such independent validation of the company is particularly gratifying at a time when we are fundraising for a pre-IPO round," she added.


Avaya to launch solutions for Pharma industry

Avaya GlobalConnect, an enterprise converged communication solutions provider, will shortly come up with specific communication solutions for the pharmaceutical industry. Avaya is working towards offering its customers Intelligent Communication solutions, with seamless communication and business applications that give workers, customers and processes the ability to be linked at the right time, by the right medium over any network.

Ritesh Jayswal, director, industry solutions, Avaya India, said, "We are already working on different verticals for providing communication solutions including pharmaceutical industry. We expect that the pharma specific solution would be ready for launch in next six months time."

Avaya GlobalConnect has opened a customer studio in Mumbai, which is the first of its kind in India and in the Asia-Pacific region. The customer studio is designed to provide customers a first hand experience of powerful intelligent end-to-end communication solutions that Avaya GlobalConnect, and its partners from around the world can bring to their business. "The customized demonstrations are developed after experts carefully study the client's vertical industry, challenges and current infrastructure. The team then provides a solution that would best address customer needs to increase process efficiency, employee productivity and save costs," added Jayswal.

Niru Mehta, managing director and vice chairman, Avaya GlobalConnect, said, "Since communication solutions are an integral and critical aspect of business, it is understandable that companies would want to be convinced of any communication solution they may want to implement. The customer studio offers our customers an opportunity to experience the power of personalized intelligent communication so that they can make confident and informed decisions."


PHFI gets government grant of Rs 65 crore

The Public Health Foundation of India (PHFI) received a one-time grant of
Rs 65 crore towards the initial corpus of the Foundation from the Central government. The Cabinet Committee on Economic Affairs (CCEA) has approved this one-time grant towards the initial corpus of the Foundation. With this, Dr Montek Singh Ahluwalia, deputy chairman, Planning Commission, Government of India and TKA Nair, principal secretary to the Prime Minister of India, will be part of the PHFI Governing Board.

Prof. K Srinath Reddy, renowned cardiologist and HOD, cardiology–AIIMS, has been deputed as president to the Public Health Foundation of India.

Prof. Srinath Reddy has served on many WHO expert panels and heads the WHO Collaborating Centre on Epidemiology and Prevention of Cardiovascular Disease. Last year, Prof Reddy received the Padma Bhushan and also the Queen Elizabeth Medal for his outstanding contributions to public health.

Prof Reddy said, "It is indeed a privilege to lead such an initiative that offers a major opportunity to make a substantial contribution to the Indian public health scenario."

Rajat Gupta, chairman of the Board of the PHFI and senior partner worldwide, McKinsey & Company, welcoming the approvals, said they were a reaffirmation of the government's confidence in and commitment towards the PHFI.

Since approvals from the CCEA, and contributions from private donors and the Bill & Melinda Gates Foundation, PHFI today has a total corpus of over
Rs 200 crore. Looking ahead, the Foundation's immediate goal is to open the doors of the very first school of public health i.e. Indian Institute of Public Health (IIPH) by June 2008. As a result, the PHFI has undertaken innovative measures to build a strong faculty pool.

To this effect, it has entered into academic partnerships with the Association of Schools of Public Health (ASPH), USA and The London School of Hygiene and Tropical Medicine. These would soon be extended to include partnerships with public health institutions in other parts of the world, especially those in developing countries.


Serum Institute gets WHO nod to supply Q-Vac to UN agencies

Serum Institute of India has received pre-qualification certification from World Health Organisation (WHO) for supplying Q-Vac (combination of DPT and Hep B vaccine) to UN agencies.

Speaking to BioSpectrum, Dr Cyrus Poonawalla, chairman, Serum Institute of India, said, "It is a major milestone for us as ours is the first Indian company to get pre-qualification for combination vaccine from WHO to supply to the UN agencies." He further said, "There are many global players who are into manufacturing of DPT and Hep B combination vaccine but they don't have the pre-qualification from the WHO. We can expect an immediate rush from UNICEF and other UN agencies for the combination vaccine, which is in an acute shortage worldwide because only the big pharmas that are offering it at exorbitant prices."


... picks up 14% stake in Lipoxen PLC

Serum Institute of India (SIIL) has picked up a 14 percent stake in Lipoxen PLC, a UK-based biopharmaceutical company specializing in the development of differentiated biologicals, vaccines and oncology drugs. Lipoxen has raised £2.6 million in new funds from the SIIL through a subscription agreement and associated warrant agreement.

"We are excited about our strategic investment in Lipoxen and feel their technology is a key component to our strategy to create high value differentiated biologics and vaccines. Our investment and increased strategic collaboration was prompted by Serum's desire to become a large contributor in the biopharmaceutical world and by the very positive preliminary scientific data," said Dr Cyrus Poonawalla, chairman and managing director, Serum Institute of India.

The funds raised through the subscription would allow Lipoxen to drive clinical development of its pipeline of potential protein drugs and vaccines into clinical trials and appoint a leading biologic CRO. It will also allow Lipoxen to recruit additional laboratory staff in order to capitalize on the potential to broaden the company's revenue generating collaborations. Lipoxen's proprietary delivery technologies are attracting significant interest and it is already co-developing products with Serum Institute. This agreement will enable Serum Institute diversify into oncology and recombinant products which will be differentiated from the generics existing in the market.

Pursuant to the subscription agreement, Lipoxen has agreed to issue to SIIL 10,000,000 ordinary shares at a subscription price of 26 pence per share ("Subscription Shares"). Lipoxen has also entered into a warrant agreement with SIIL pursuant to which SIIL has the right to subscribe for up to 2.7 million ordinary shares for a period of two years from August 3, 2006 at a subscription price of 35 pence per share. As part of these agreements, SIIL has also been granted the right to appoint a non-executive director to the board of the company.

SIIL has entered into a licensing agreement with Lipoxen in a major product development program during the first quarter last year. The agreement involves eight new product candidates in total, including protein drugs such as GCSF and EPO, anti-cancer drugs and vaccines. SIIL provides the active ingredients and Lipoxen provides the enhanced delivery systems.

Claris to buy technology for GCSF Claris to buy technology for GCSF

Claris to buy technology for GCSF

Claris Lifesciences is considering buying technology to develop and manufacture biotechnology products like granulocyte-colony stimulating factor (GCSF) and interferon. Claris imports erythropoietin from North China Pharmaceuticals Genetic Bio-Technology Company in finished form and markets it in India under the brand name Epotin.

Sushil Handa, founder CEO, Claris Lifesciences, said, "Biotechnology is a high growth business area for Claris. We are committed to research and have set up a Claris Research Foundation. The Foundation has initiated its research program in the field of biotechnology with a focus on R&D of monoclonal antibodies and recombinant technology. A scientific team of 200 has been working on other areas like development of innovative products and new drug delivery systems (NDDS) for the management of critical illnesses. "

He further said, "In addition to catering to the Indian market, we are also looking at exporting the biotechnology product to Latin American countries and Brazil. At present Epotin is in the third position in the local market. We are setting up a facility for pre-filling of syringes and vials for EPO at our plant, which will be operational by end of this year. This will help us increase our market share in India. We look at achieving a $10-million figure from the sale of biotechnology products by 2009, by which we are set to become a Rs 1,000-crore company."


Protect our rich national biodiversity: Sibal

"India has a rich biodiversity. It is our national treasure and we must ensure its protection," said Kapil Sibal, the Union Minister for science and technology and earth sciences.

Chairing the Fourth meeting of the National Bioresource Development Board (NBDB) in New Delhi, Sibal lauded the efforts undertaken by the Board in areas such as digitizing inventories on bioresources, prospecting for genes and molecules, resource based programmes and capacity building. The minister emphasized the need for more funds to scale up various activities of the Board and also suggested that the Board should be made an autonomous body.

During the meeting, Kapil Sibal released Jeeva Sampada, the first database of digitized inventories on bioresources packaged in nine CDs containing information on plant resources (Sasya Sampada), animal resources, microbial resources and marine resources.

Over 400 scientists from 150 centers across the country have worked together to complete the task. Sibal also launched the Indian Bioresources Information Network (IBIN), the first web enabled portal for proper integration of spatial and non-spatial data. This is the first comprehensive information system, integrating all aspects of bioresources related data (spatial and non-spatial).


Merck launches new anti-cancer drug

Merck Specialities, the Indian subsidiary of Merck KGaA, has announced the introduction of ERBITUX, a new gold standard targeted therapy for the treatment of Colorectal Cancer (CRC) in India.

ERBITUX, which has already obtained approval for the treatment of CRC in 53 countries, is a significant step forward in the management of cancer in India. It works by targeting the Epidermal Growth Factor Receptor (EGFR) which is found on the surface of cells and is involved in the stimulation of cellular growth, replication and/or differentiation when stimulated by growth factors. EGFR has been shown to be involved in the development and progression of many common types of cancers.

In India, there are about 3.5 million cases of cancer and about 35,000 are found to suffer from CRC. About two-thirds of the new CRC patients diagnosed in India each year are men.

ERBITUX, either alone or in combination with chemo or radiotherapy offers an effective, innovative and targeted approach to enhancing cancer treatment. When used alone, ERBITUX has the power to shrink tumors. When combined with chemo or radiation therapy, ERBITUX significantly enhances the efficacy of chemo and radiotherapy.

Wayne Paterson, regional head of oncology, Asia Pacific Merck Pte Ltd,
Singapore, said, "ERBITUX is the therapeutic backbone to which other therapies may be added in the future. Despite the use of the best available chemotherapy agents, patient outcomes remain poor in advanced disease and this has led to the search for targeted therapies such as ERBITUX."

Dr Marek Dziki, MD, Merck Specialities said, "Merck is committed to developing targeted therapies that specifically attack cancer cells. It is our hope that this targeted approach will offer people living with cancer the best chance for prolonged survival while at the same time allowing them to avoid many of the toxicities that negatively impact their lives."


Gilead signs new Viread pact

Gilead Sciences has announced that the company has signed non-exclusive license agreements to provide generic versions of tenofovir disoproxil fumarate (sold by Gilead under the brand name Viread) to three generic manufacturers in India. These license agreements grant to Emcure Pharmaceuticals, Hetero Drugs and Strides Arcolab the rights to produce and distribute generic versions of tenofovir to 95 low-income countries around the world, including India.

The license agreements require that the generic manufacturers meet certain national and international regulatory standards and include a technology transfer to enable expeditious production of large volumes of high-quality generic versions of tenofovir. In addition, these agreements allow the manufacture of commercial quantities of both active pharmaceutical ingredient (API) and finished product. Gilead continues to pursue license agreements with additional Indian generic manufacturers and is currently in ongoing discussions with a number of Indian companies.

"We are pleased to have finalized agreements with Emcure, Hetero, and Strides Arcolab and anticipate granting additional licenses over time to help meet the needs of patients in the developing world," said John C Martin, president and CEO of Gilead Sciences. "We hope that competition among multiple manufacturers will result in even lower prices for Viread in the developing world than what Gilead is currently offering."


Mahindra Gesco to invest Rs 150 crore in biotech SEZ

Mahindra Gesco Developers has announced that the Board of Approval, Government of India, has approved the Mahindra Group's proposal for sector specific special economic zone for biotechnology sector to be set up at Ghodbunder Road, Thane, a suburb of Mumbai. The proposed SEZ will be spread over an area of 72 acres owned by the company and will be developed by the company, a subsidiary of Mahindra & Mahindra Ltd. The proposed SEZ will provide the same world class standards that have made the Mahindra World City SEZ in Chennai a big success.

The SEZ will involve investment of approximately Rs 150 crore and is expected to generate direct employment for more than 2000 people.

Arun Nanda, executive director and president, infrastructure development sector, Mahindra & Mahindra, said, "Biotechnology firms are looking for world class facilities to support their global expansion. The Mahindra Group, with its first mover advantage in the SEZ sector, is uniquely positioned to offer the biotech industry world class and state-of-the-art facilities. This SEZ is a perfect fit in our strategy to create a 'plug-in and play' environment for global giants. It will have the dual advantage of the Mahindra World City promise of world class infrastructure and its proximity to the commercial hub of Mumbai".

The SEZ will offer all the benefits of convenience, high productivity and lowered costs, living community in close proximity, while providing a truly international and soothing environment. The SEZ shall attract investments from global biotechnology majors who are attracted by the wealth of talent in India. The SEZ will offer specialist business zones with customized infrastructure to give companies a competitive edge.


Ranbaxy gets nod to manufacture, sell anti-AIDS drug

Ranbaxy Laboratories Limited (RLL) has announced that the company received approval to manufacture and market Triviro-LNS kid and Triviro-LNS kid DS, both triple ARV combinations for children, in India. The company has also filed the product with WHO Geneva for pre-qualification.

While Triviro-LNS kid contains Lamivudine 20mg, Nevirapine 35mg, and Stavudine 5mg, Triviro-LNS kid DS contains the drugs in 40mg, 70mg and 10mg strengths respectively. The products are bio-equivalent with the individual liquid formulations of the originators. The products are indicated for treatment of HIV infection in children.

"We hope that with these new formulations, we will be able to make accessible, a high quality and convenient treatment to a large number of HIV-positive children who are presently among the therapeutically most neglected", said Malvinder Mohan Singh, CEO and MD, RLL. Presently HIV/AIDS kills about 500,000 children every year. Both the approved formulations are scored dispersible tablets, and are pleasantly flavored. The products are designed to deliver three ARV drugs together in recommended strengths and simplify delivery of a more accurate treatment to children in resource poor settings.


Geno-Cluster shines

Jalaja Technologies' latest offering, Geno-Cluster, a suite of high-end software applications based on concepts, which are fundamental to comparitive genomics, has been successfully sold to over 11 research and academic institutions across India like the IICB, Dr Naidu's Global Academy , IVRI-Lucknow , Pune University and Rajiv Gandhi Centre for Biotechnology to name a few.
By the end of September 2006, the company expects to have another 10 more prestigious installations across the country and a few more across the globe, a release said. The product was recently purchased by the Genome Sciences Center (GSC), RIKEN Suehiro-cho, Tsurumi-ku, Yokohama City, Japan.


TCS to develop software for Sequenom TCS to develop software for Sequenom

TCS to develop software for Sequenom

Tata Consultancy Services (TCS) has entered into an agreement with Sequenom, a US-based company, to develop software solutions for the latter. Sequenom is a Nasdaq-listed company that provides genetic analysis products.

"It is a multi-million dollar deal," said Dr M Vidyasagar, executive vice-president and head, Advanced Technology Centre, TCS. He did not specify the size of the contract.

All developments under the agreement will utilize modern development practices and conform to the relevant US Food and Drug Administration regulatory standards. The software to be developed will provide components that provide access to public and private life sciences databases, integration of bio-informatics and computational biology tools within the framework and enable design and execution of workflows.

"Sequenom will not own the database," Dr Vidyasagar added. TCS's software package, Bio-Suite, would be integrated within the framework.


Brain League, Edutech tie up to provide Value IPR

Brain League, an Intellectual Property service company, and Edutech, provider of enterprise wide knowledge solutions, have tied up to address the need to train employees across the enterprise in Intellectual Property Rights through Value IPR, an e-Learning tool aimed at businesses.

The companies say that Value IPR can deliver the IPR e-Learning modules to as many people within the organization as required, making it an effective enterprise-wide IPR training device. It helps in sensitizing the entire employee force to various aspects of IP.

Kalyan C Kankanala, chief knowledge officer, Brain League, said, "To be competitive in this era of globalization, it is important for knowledge-driven companies to develop and protect intellectual property, which provides competitive and business advantage. In order to develop and utilize intellectual property (IP) for optimal commercial benefit, companies have to build an IP culture and hygiene among their employees."

Sanjay Bettadapura, manager, life sciences, Edutech, said, "Value IPR offers organizations a series of modules to help employees with IPR awareness in a comprehensive step-up way. The first module, titled Impact on Business, talks about the value of IP rights to businesses and the positive impact it can have on profits, along with an overview of different species of IP."


Ranbaxy invalidates Pfizer's Lipitor US Patent

Ranbaxy Laboratories has announced that the US Court of Appeals for the Federal Circuit (CAFC) handed down a judgment in its case challenging two key atorvastatin patents held by Pfizer. CAFC sided with Ranbaxy by invalidating one of Pfizer's atorvastatin patents, US Patent No. 5,273,995 ('995) and overturning Delaware District Court judgement in that regard. However, the official release noted that it affirmed the portion of the judgement, which held that Ranbaxy's product infringes Pfizer's US Patent No. 4,681,893 ('893). The ruling followed a hearing in the US CAFC, which took place on May 4, 2006.

Jay R Deshmukh, senior vice president, global intellectual property for Ranbaxy said, "We are pleased by the court's decision on the '995 patent and are evaluating our options with respect to the '893 patent."

Subject to the appellate process and market authorization by the US FDA, Ranbaxy now has the opportunity to bring the launch date forward to March 2010 from June 2011 with 180-day exclusivity in the US market.

JK Agri Genetics signs accord with NBRI for new Bt cotton technology

Hyderabad-based JK Agri Genetics has entered into an agreement with the National Botanical Research Institute, Lucknow (NBRI) to commercialize their new Bt cotton technology using Cry 1EC gene in India.

JK Agri genetics recently launched the first indigenously developed Bt cotton in the Indian market after obtaining clearances from the GEAC during Kharif 2006, wherein the product was developed under collaborative research with BREF-IIT Kharagpur. The new gene (Cry IEC) developed by NBRI would be pyramided with the recently released material carrying Cry 1Ac gene. This elite Bt cotton will give broader insect resistance coverage, particularly against Spodoptera (tobacco caterpillar) and expected to provide season long uniform protection of the target pests throughout the entire field. Besides, the new product is expected to help in delaying the resistance development in cotton bollworm complex. Currently cotton varieties containing Bt do not offer acceptable control of Spodoptera.

JK Agri Genetics is expected to complete the regulatory studies and launch this elite new generation product in few years. Farmers who would plant this new product (CRY 1 EC + Cry 1 AC) can significantly reduce the use of externally applied expensive chemical insecticides, including organophosphate and synthetic pyrethroid products that are used to control these pests.


IPC, USP sign MoU to promote quality of medicines

The Indian Pharmacopoeia Commission (IPC) and the United States Pharmacopeial Convention (USP) have signed a Memorandum of Understanding (MoU) to promote greater co-operation through the exchange of information, and to increase awareness of the importance of the quality and safety of medicines.

The MoU was signed on behalf of the IPC by Prasanna Hota, chairman, IPC and secretary (Health), Union Ministry of Health and Family Welfare, and on behalf of the USP by Dr Roger L Williams, executive vice president and CEO.

Hota said the MoU signified the common goal of the two pharmacopeial organizations-to promote the quality and safety of medicines.

Dr Williams said, "This MoU marks a major step forward in cementing our relationship with the IPC. Over the years, we have had the distinct pleasure of working with this distinguished body, as well as Indian national and state governments and Indian manufacturers on many scientific and policy initiatives. With the signing of this MoU, we look forward to expanding that co-operation through more collaborative work with the IPC."


Glenmark gets DCGI nod to conduct Phase II trials

Mumbai-based Glenmark Pharmaceuticals has received approval from The Drug Controller General of India (DCGI) to initiate Phase II trials for its novel, in-licensed anti-diarrhoeal product, crofelemer. The trial is expected to commence in calendar 2006 and will involve 60 adult patients suffering from acute diarrhoea in a prospective, randomized, parallel group using a controlled double-blind placebo method. The trial will be concluded within three months from the start of dosing.

Glenmark signed a development and commercialization alliance with Napo Pharmaceuticals in July 2005. Under the terms of the agreement, Glenmark will be responsible for marketing Crofelemer in over 140 countries, including India, for three indications, viz. AIDS diarrhoea, infectious diarrhoea and paediatric diarrhoea. In return, Glenmark will provide low-cost and large-scale manufacturing in FDA approved manufacturing facilities and upon marketing will pay royalties to Napo. Glenmark expects to launch the drug in 2008 in the first territory. The company is also working on a development plan for the other indications of AIDS related diarrhoea and paediatric diarrhoea.


Lupin gets DCGI nod for Phase-II trials for Desoside-P

Lupin has received approval from Drugs Controller General (India) (DCGI) to conduct Phase-II clinical trials for the molecule LL-42 18 (Desoside-P). The company received permission to continue Phase-II clinical trials on the compound, LL-42 18, after DCGI found the clinical Phase-I data of the molecule to be satisfactory.

Lupin is planning to begin clinical trials at five or six centers immediately, according to a release. "We are delighted that our Phase-I data has been found to be satisfactory for us to proceed with further clinical trials. We are very excited with taking the molecule forward, and look forward to meeting this otherwise unmet market need," chairman Desh Bandhu Gupta said.

LL-4218, a pure molecule, is obtained from a plant source and is intended for the treatment of chronic stable plaque type psoriasis.

This molecule's novel mechanism of action leads to marked psoriatic lesion improvement without any toxic effects.


Eli Lilly and Novo Nordisk get GEAC's nod for further import

The Genetic Engineering Approval Committee (GEAC) has given permission to Eli Lilly and Company (India) for revalidation for import and marketing of its recombinant drugs, Drotrecogin alpha (activated) and Xigris and Humatrope (Somatropin) in India for two more years.

Earlier Eli Lilly and Company (India) received the committee's nod for Xigris in July 2002 for import and marketing for a period of four years. The GEAC had also approved the import and marketing of Somatropin Injection (r-DNA) for a period of four years in its 13th meeting held in November 1996. Subsequently in accordance with the provisions of Rule 13(2) of the 1989 Rules, the approval was revalidated for a period of two years at its meeting held on July 2002 and July 2004.

In similar case Novo Nordisk too received the ' no objection' from GEAC for import and marketing of human Insulin (DNA origin) in India for two more years. Novo Nordisk received the GEAC's nod for the first time in July 2002 for import and marketing of human Insulin (DNA origin) and its formulations for a period of four years. In accordance with the provisions of Rule 13(2) of the 1989 Rules, the GEAC Conveyed its 'No Objection' for revalidation of GEAC permission for two more years at its meeting held in July 2006. However, the Committee was of the view that renewal of GEAC permission is not necessary in respect of r-Pharma proposals that do not require the approval of GEAC as per the new procedure.


Lyric Labs expands to Bangalore

Coimbatore-based Lyric Labs, a medical translation services company, has launched its operations in Bangalore to cater to the needs of biotech, IT and pharma majors.

Lyric Labs offers services such as translation, multi lingual type setting of the most sensitive documents of pharmaceutical companies, CROs, manufacturers of medical and surgical devices, biotech companies, pertaining to clinical protocols, patient information, clinical trials, patient questionnaires and scientific papers.

VR Sasidar, CEO, Lyric Labs, said, "Our expertise lies in localization and not only translation. Handling multi pair translation at a given time with uniform pricing is the company's key strength. The need for translation is everywhere, all segments of industry right from software development to life science and manufacturing companies. We have plans to open up our customer support centers in Delhi and Hyderabad by early 2007."

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email